Stemline Therapeutics

Stemline Therapeutics is owned by Menarini Group. Menarini Group has a direct presence in 4 countries.

Menarini Group has 3 subsidiaries including Berlin Chemie, Menarini APAC and Stemline Therapeutics.

They are in:

• Pharmaceuticals75%
• Biotechnology25%

View the org chart displaying its 8 main executives

Most searched biographies at Stemline Therapeutics

• Ivan Bergstein, Director, Chief Executive Officer and President
• David Gionco, Senior Vice President of Finance and Chief Accountin...
• Ken Hoberman, Chief Operating Officer

Create your alert
to follow the executive moves at Stemline Therapeutics.

Menarini Group has 2,274 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).
• Nurix Therapeutics has just announced a $175 Million fundraising (posted on April 13 2024).
• Nuvation Bio has announced the acquisition of AnHeart  (posted on April 12 2024).

Popular contacts in Biotechnology

• Vik Bajaj - Director at Interline Therapeutics
• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Stemline Therapeutics

• RSS News Feeds | Stemline Therapeutics
• Menarini Group Completes Acquisition of Stemline Therapeutics | Stemline Therapeutics
• Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million | Stemline Therapeutics
• Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020 | Stemline Therapeutics
• Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results | Stemline Therapeutics
• Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference | Stemline Therapeutics
• Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers | Stemline Therapeutics
• Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference | Stemline Therapeutics
• Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting | Stemline Therapeutics
• Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer | Stemline Therapeutics
• View more press releases Close

Social media about Stemline Therapeutics

• Stemline Therapeutics on Wikipedia, Google News & Yahoo Finance
• Stemline Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Ivan Bergstein

Call Stemline Therapeutics at +1 646...

View the org chart

Register to receive your alert

Report an error